rs3135506 — APOA5 S19W
Triglyceride metabolism - affects fasting triglyceride levels and cardiovascular risk
Details
- Gene
- APOA5
- Chromosome
- 11
- Risk allele
- C
- Protein change
- p.Ser19Trp
- Consequence
- Missense
- Inheritance
- Codominant
- Clinical
- Risk Factor
- Evidence
- Strong
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Category
Nutrition & MetabolismAPOA5 — Triglyceride Metabolism
APOA5 (Apolipoprotein A5) plays a key role in regulating triglyceride
levels. Discovered in 200111 Discovered in 2001
Pennacchio et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science, 2001 through comparative sequencing of the
APOA1/C3/A4 gene cluster, APOA5 was found to strongly influence plasma
triglyceride concentrations in both humans and mice.
The Mechanism
The S19W variant (rs3135506) causes a serine-to-tryptophan substitution at position 19 (p.Ser19Trp) in the signal peptide22 The signal peptide is a short amino-acid sequence that directs a newly made protein for secretion out of the cell of the APOA5 protein. This disrupts the signal peptide function, reducing APOA5 secretion into the bloodstream by approximately 50%. Since APOA5 normally lowers triglycerides by stimulating lipoprotein lipase activity and inhibiting VLDL production, reduced secretion leads to higher triglyceride levels.
The Evidence
The ICARIA study33 ICARIA study
Loria et al. Additive effects of LPL, APOA5 and APOE variant combinations on triglyceride levels and hypertriglyceridemia. BMC Med Genet, 2010 demonstrated that
APOA5 S19W carriers have an independent, additive triglyceride-raising
effect. Carriers of the rare allele show significantly higher levels of
large VLDLs (+133%) and small dense LDLs (+34%), creating a proatherogenic
lipid profile.
Guardiola et al.44 Guardiola et al.
Guardiola et al. APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis. Atherosclerosis, 2015 confirmed
that this variant predisposes carriers to atherogenic dyslipidemia and
subclinical atherosclerosis — measurable thickening of artery walls even
before symptoms appear.
High triglycerides are an independent risk factor for cardiovascular disease and pancreatitis55 Very high triglycerides (above roughly 500 mg/dL) can trigger acute pancreatitis, a serious inflammation of the pancreas.
Practical Implications
The C allele is found in about 6% of Europeans and up to 14% of Hispanics, but is rare (<2%) in East Asian and African populations. Dietary interventions — especially limiting refined carbohydrates and increasing omega-3 intake — are the primary management strategy.
Interactions
Triglyceride-raising effects are additive when combined with variants in LPL and APOE genes. If you also carry APOE E4 (rs429358), your overall cardiovascular risk is compounded.
Nutrient Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Normal triglyceride metabolism
You have normal APOA5 function, shared by about 88% of Europeans. Your triglyceride levels respond typically to diet and lifestyle.
One variant - higher triglyceride tendency
You carry one copy of the S19W variant, found in about 11% of Europeans. This reduces APOA5 secretion by approximately 50%, leading to higher triglyceride levels. Carriers show significantly higher levels of proatherogenic large VLDLs and small dense LDLs.
Two variants - significantly higher triglycerides
You have two copies of the S19W variant, a rare genotype (~1% of Europeans). You have a strong genetic tendency toward higher triglyceride levels due to severely reduced APOA5 secretion. This significantly increases your risk of cardiovascular disease and potentially pancreatitis with very high triglyceride levels.
Key References
Pennacchio et al. — discovery of APOA5 as a novel apolipoprotein influencing triglycerides in humans and mice (Science 2001)
Loria et al. — ICARIA study showing additive triglyceride-raising effects of APOA5 + LPL + APOE variant combinations
Guardiola et al. — APOA5 variants predispose to atherogenic dyslipidemia and subclinical atherosclerosis
Mattei et al. — S19W effects on triglycerides influenced by sex and menopause status
Sharma et al. — comprehensive 15-year review of APOA5 genetic epidemiology and triglyceride regulation